Peptides and Biologics in Psychiatry: A Clinician's Field Guide

Psychiatry has always been a small-molecule specialty. Our drugs are little organic compounds that slip across the blood–brain barrier and dock onto receptors and transporters. But two other classes of medicine — peptides (short chains of amino acids) and biologics (large, engineered proteins such as monoclonal antibodies) — are pressing into psychiatric territory from the directions of endocrinology, immunology, and sleep medicine. Some of this overlap is real and evidence-based; some of it is aspirational; and a striking amount of it is happening in wellness clinics, outside the evidence base entirely, driven by patients who will ask you what you think. This chapter is a field guide to all three layers. It is written so a student can learn the biology from scratch and a practicing clinician can walk away able to counsel a patient about a peptide their gym trainer recommended.

Why the boundary is blurring

Three facts of biology explain why molecules built for the body are turning up in the brain's specialty. First, metabolism and mood share circuitry: the same hypothalamic and mesolimbic systems that regulate appetite and reward also shape motivation, anhedonia, and craving. Second, inflammation touches the brain: a meaningful subgroup of patients with depression or schizophrenia show elevated inflammatory markers, and cytokines influence neurotransmitter metabolism, neuroplasticity, and mood. Third, the sleep–wake system is peptidergic: orexin (hypocretin), the master switch of wakefulness, is itself a neuropeptide. Once you see psychiatric symptoms as partly downstream of metabolism, immunity, and arousal, it becomes obvious why incretins, antibodies, and peptides would find a foothold here.

A quick primer on the molecule types, because the differences matter clinically. Peptides are short amino-acid chains — bigger than classic drugs, usually injected because the gut would digest an oral version, and often mimicking the body's own signaling molecules. Biologics are large proteins, most famously monoclonal antibodies ("-mab" drugs), that bind a single target with exquisite specificity but generally do not cross the blood–brain barrier well, which is a central limitation for CNS use. Both are more expensive to manufacture and monitor than small molecules, and both raise manufacturing-quality and immune-reaction concerns that pills rarely do.

The incretin peptides: GLP-1 and GLP-1/GIP

The GLP-1 receptor agonists — semaglutide, liraglutide, and the dual GLP-1/GIP agonist tirzepatide Approved (for diabetes and obesity) — are the most consequential peptides now touching psychiatry, precisely because so many of our patients already take them. They penetrate the CNS, dampen neuroinflammation, modulate reward and "food noise," and improve insulin signaling, all mechanisms with plausible psychiatric relevance.

The mental-health data are genuinely bidirectional, and honesty about that is the clinician's job:

• Reassuring signals: large cohort analyses associate semaglutide with a lower risk of worsening mental illness (adjusted hazard ratios near 0.58 in some datasets), with parallel signals for liraglutide, plus reductions in binge-eating behavior. GLP-1 agonists are also gaining traction as candidates for alcohol and other substance use disorders, where the reward mechanism is directly on point.
• Cautionary signals: the European Medicines Agency has reviewed reports of suicidal ideation and self-harm associated with GLP-1 agonists, and pharmacovigilance databases carry psychiatric adverse-event reports (depression, anxiety). Fatigue is a common side effect that can masquerade as, or worsen, low energy.

Two developments sharpen the psychiatric picture. First, the investigational dual GLP-1/GIP peptide brenipatide Late pipeline (from the tirzepatide lineage) is now in a Phase 3 adjunctive trial for major depressive disorder and Phase 2 programs touching bipolar disorder and schizophrenia — the first time an incretin peptide is being developed as a psychiatric drug rather than borrowed from metabolism. Second, the cognitive story cooled: the large Phase 3 EVOKE/EVOKE+ trials of oral semaglutide in early Alzheimer's disease failed Failed to slow cognitive decline despite small favorable shifts in some CSF biomarkers. That negative result is an important corrective to the "GLP-1 fixes the brain" narrative.

Oxytocin: the seductive neuropeptide

Oxytocin, the "social bonding" neuropeptide, has been the most-studied peptide for psychiatric symptoms — social cognition, anxiety, and especially autism spectrum disorder Early / mixed. It is also the field's most instructive disappointment. The mechanistic rationale is compelling and the early studies were exciting, but the definitive data have underwhelmed: a large NEJM randomized trial of intranasal oxytocin in children and adolescents with autism showed no significant benefit on social or cognitive functioning over 24 weeks, and meta-analyses find, at best, inconsistent effects that emerge only at higher doses. Research continues — including precision-medicine efforts to find the responder subgroup and trials in autism with co-occurring intellectual disability — but oxytocin is a cautionary tale about how far a beautiful mechanism can travel on hope before rigorous trials catch up.

Biologics: antibodies and the inflammation hypothesis

If depression and psychosis have an inflammatory subtype, then the precision tools of immunology — monoclonal antibodies that neutralize a single cytokine — should help the right patients. This is the "molecular scalpel" idea, and it is being tested directly.

Two lessons generalize from this work. First, patient selection by biomarker (e.g., elevated CRP) is likely essential — these drugs are not for unselected depression or psychosis. Second, the effects so far are on symptoms already linked to inflammation (mood, positive symptoms), not on the cognitive and negative domains patients most want addressed. Add the practical hurdles — blood–brain-barrier penetration, cost, injection and monitoring burden — and biologics remain an investigational, precision-psychiatry frontier rather than a near-term tool. They connect naturally to the psychoneuroimmunology literature covered elsewhere on the site.

The three complaints that drive the peptide market

Most patient questions about peptides cluster around three symptoms: poor sleep, low energy, and poor focus. It is worth separating, for each, what is genuinely approved or in serious development from what is being sold on hope.

Sleep. The legitimate, evidence-based agents here are small molecules, not peptides: the dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant). The peptide angle — delta sleep-inducing peptide (DSIP/emideltide) Gray-market — is decades old with scant modern efficacy data. The orexin system, which unifies the real sleep and wake story, has its own chapter.

Energy. Marketed "energy" peptides such as MOTS-c and SS-31, and the cofactor NAD⁺ Preclinical, are promoted for "cellular energy" and mitochondrial function. The mechanisms are real and interesting; the human clinical evidence is preliminary to absent, and a 2025 review could only propose (not demonstrate) benefit in chronic fatigue syndrome. GLP-1 agents and the approved wakefulness drug solriamfetol are the evidence-based options for genuine fatigue and sleepiness.

Focus. The real news in focus is small-molecule (centanafadine's ADHD decision; solriamfetol's positive ADHD trial — see the pipeline chapter). The peptide "nootropics" — Semax and Selank (human data almost exclusively from non-independent Russian clinical settings, unreplicated in the West), Cerebrolysin (the most-tested, with mixed dementia data), and dihexa (whose foundational paper was retracted in April 2025 for data fabrication) — range from under-studied to discredited Gray-market. They mostly act by boosting neurotrophic signaling (BDNF, NGF), which is exactly why they appeal — and exactly why the evidence bar should be high.

The July 2026 FDA compounding decision

This chapter is being published during a pivotal regulatory moment. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to weigh whether seven peptides belong on the 503A bulk drug substances list — which would let compounding pharmacies prepare them to prescription. The agents include BPC-157, KPV, TB-500, and MOTS-c (day one) and emideltide/DSIP, Semax, and Epitalon (day two). This follows the FDA's April 2026 removal of these peptides from the "Category 2 — safety concerns" bucket that had barred their compounding since 2023, amid public pressure from HHS leadership to ease access, and over warnings from the agency's own scientists.

BPC-157 is the cautionary archetype: an unapproved drug, previously flagged for safety concerns, with no established safe human dose, documented illegal inclusion in "wellness" and anti-aging products, and real contamination risk from unregulated sourcing. Whatever the committee recommends, the clinical reality is that patients are already obtaining these peptides through gray-market channels. Your value to them is not reflexive dismissal but an honest account of the mechanistic appeal, the thin or absent human evidence, and the sourcing and safety risks — the same evidence-literate posture you would bring to any unproven intervention.

A field guide at a glance

Conclusion

The overlap between psychiatry and the world of peptides and biologics is best understood as three concentric rings. At the center are agents with real, if still-maturing, evidence and clear psychiatric development: the incretins already in your patients' medicine cabinets, and brenipatide following behind. In the middle ring are precision biologics — anti-cytokine antibodies for biomarker-selected patients — that are scientifically serious but years from routine use. In the outer ring is a fast-growing gray market of wellness peptides for sleep, energy, and focus, propelled by a shifting regulatory wind and by patients who will ask you about them whether or not the evidence has arrived. The clinician's task across all three rings is the same: know the biology well enough to separate mechanism from proof, and counsel from evidence rather than enthusiasm. The companion chapters on the modern pipeline and the orexin system extend two of these threads in depth.